Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies

Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies

To accommodate waning COVID-19 vaccine immunity to emerging SARS-CoV-2 variants, variant-adapted mRNA vaccines have been introduced. Here, we examine serological responses to the BA.1 and BA.4-5 Omicron variant-adapted BNT162b2 COVID-19 vaccines in people with lymphoid malignancies. We included 233...

Full description

Bibliographic Details
Main Authors: Line Dam Heftdal, Cecilie Bo Hansen, Sebastian Rask Hamm, Laura Pérez-Alós, Kamille Fogh, Mia Pries-Heje, Rasmus Bo Hasselbalch, Dina Leth Møller, Anne Ortved Gang, Sisse Rye Ostrowski, Ruth Frikke-Schmidt, Erik Sørensen, Linda Hilsted, Henning Bundgaard, Peter Garred, Kasper Iversen, Caroline Sabin, Susanne Dam Nielsen, Kirsten Grønbæk
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Viruses
Subjects:
lymphoid malignancies
COVID-19
vaccine
booster
variant
SARS-CoV-2
Online Access:https://www.mdpi.com/1999-4915/16/1/11

Internet

https://www.mdpi.com/1999-4915/16/1/11

Similar Items